X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://pharmaphorum.com/news/smart-sensor-cleared-use-az-asthma-copd-inhalers
https://www.prnewswire.com/news-releases/calliditas-therapeutics-to-present-nefecon-data-at-the-isn-world-congress-of-nephrology-april-13--16-in-buenos-aires-302110404.html
https://www.accesswire.com/849309/bausch-health-canada-inc-announces-first-public-drug-plan-listings-for-pruceris-budesonide-aerosol-foam-to-help-address-the-unmet-need-for-the-treatment-of-mild-to-moderate-distal-ulcerative-colitis-in-adults
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-enters-exclusive-pact-to-distribute-astrazenecas-anti-asthma-drug-symbicort-in-india/articleshow/108397321.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.prnewswire.com/news-releases/calliditas-announces-an-additional-seven-year-orphan-drug-exclusivity-period-for-tarpeyo-302081089.html
https://endpts.com/takeda-wins-long-awaited-us-approval-for-first-oral-drug-for-eosinophilic-esophagitis/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-7-2024-67267.pdf
https://www.prnewswire.com/news-releases/everest-medicines-announces-new-drug-application-acceptance-of-nefecon-in-taiwan-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-302022659.html
https://www.fiercepharma.com/pharma/calliditas-wins-over-fda-full-approval-broader-label-tarpeyo
https://www.prnewswire.com/news-releases/everest-medicines-partner-calliditas-therapeutics-announces-nefecon-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-slow-kidney-function-decline-302020586.html
https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-full-approval-of-tarpeyo-for-the-treatment-of-iga-nephropathy-301904398.html
https://www.prnewswire.com/news-releases/viatris-announces-launch-of-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-the-first-fda-approved-generic-version-of-symbicort-for-people-with-asthma-and-chronic-obstructive-pulmonary-disease-in-partn-301888925.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-completion-of-patient-enrollment-in-nefecon-china-open-label-extension-study-301889813.html
https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/calliditas-therapeutics-submits-supplemental-new-drug-application-to-us-food-and-drug-administration-for-full-approval-of-tarpeyo-301856435.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-partner-calliditas-therapeutics-reports-positive-topline-results-from-phase-3-nefigard-trial-evaluating-nefecon-in-iga-nephropathy-301770194.html
https://www.fiercepharma.com/pharma/astrazenecas-first-class-rescue-inhaler-airsupra-wins-fda-nod-only-adult-use
https://endpts.com/astrazeneca-nabs-6-more-months-for-symbicort-patent-in-latest-court-ruling/
https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/calliditas-partner-everest-medicines-new-drug-application-for-nefecon-is-accepted-by-the-china-nmpa-301678047.html
https://www.fiercebiotech.com/biotech/yes-no-maybe-fda-panel-delivers-mixed-verdict-astrazenecas-asthma-rescue-medication
https://www.prnewswire.com/news-releases/kidney-international-publishes-results-from-nefigard-phase-3-trial-evaluating-tarpeyo-budesonide-in-iga-nephropathy-301653694.html
https://www.calliditas.se/en/kidney-international-publishes-results-from-nefigard-phase-3-trial-evaluating-tarpeyo-budesonide-in-iga-nephropathy-4246/
https://www.fiercebiotech.com/biotech/fda-nixes-eua-ambitions-eigers-covid-treatment-proposes-full-approval-pathway-instead
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-5-2022-44974.pdf
https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211699
https://www.prnewswire.com/news-releases/calliditas-therapeutics-announces-commercial-availability-and-initial-sales-of-tarpeyo-301470452.html
https://www.fiercepharma.com/pharma/sanofi-s-mighty-dupixent-chasing-behind-takeda-s-eohilia-hits-fda-rebuff-mysterious-delay
https://www.prnewswire.com/news-releases/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy-301445918.html
https://www.dgap.de/dgap/News/corporate/first-marinosolvr-platform-deal-marinomed-biotech-and-luoxin-pharmaceutical-group-stock-ltd-sign-agreement-budesolv-treat-allergic-rhinitis-greater-china/?newsID=1482231
https://www.fiercepharma.com/pharma/astrazeneca-chalks-up-double-win-for-novel-combo-asthma-rescue-inhaler
https://www.pharmatimes.com/news/az_builds_case_for_fixed-dose_albuterol_and_budesonide_combo_in_asthma_1376449
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211922
http://www.pharmafile.com/news/576057/asthma-drug-budesonide-helps-covid-19-recovery-home
http://www.pharmafile.com/news/566249/european-approval-astrazenecas-trixeo-aerospace-moderate-severe-copd
https://www.astrazeneca.com/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020.html
https://www.raps.org/news-and-articles/news-articles/2020/7/fda-approvals-roundup-tecartus-breztri-aerosphere
https://www.businesswire.com/news/home/20200729005225/en/ORTIKOS%E2%84%A2-budesonide-Once-Daily-Dose-Treatment-Mild-Moderate
https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial.html
https://www.contractpharma.com/contents/view_breaking-news/2020-05-29/wasdell-group-receives-imp-license-for-european-hq/
https://endpts.com/swedens-calliditas-seeks-75m-ipo-haul-to-bring-its-oral-steroid-to-patients-with-an-orphan-kidney-disease/
Market Place
Share 
